Last reviewed · How we verify
Docetaxel, Cisplatin, Capecitabine, Bevacizumab
Docetaxel, Cisplatin, Capecitabine, Bevacizumab is a Small molecule drug developed by Rabin Medical Center. It is currently in Phase 1 development. Also known as: Taxotere (Docetaxel), Cisplatin, Xeloda (Capecitabine), Avastin (Bevacizumab.
At a glance
| Generic name | Docetaxel, Cisplatin, Capecitabine, Bevacizumab |
|---|---|
| Also known as | Taxotere (Docetaxel), Cisplatin, Xeloda (Capecitabine), Avastin (Bevacizumab |
| Sponsor | Rabin Medical Center |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) (PHASE2)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Efficacy of Docetaxel, Capecitabine, Cisplatin, and Bevacizumab in Patients With Unresectable Advanced Gastric Cancer (PHASE2)
- Pre-operative Chemotherapy Plus Bevacizumab With Early Salvage Therapy Based on PET Assessment of Response in Patients With Locally Advanced But Resectable Gastric and GEJ Adenocarcinoma (PHASE2)
- Phase I/II Study of Weekly Docetaxel and Cisplatin Together With Capecitabine and Bevacizumab in Advanced Gastric Cancer (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Cisplatin, Capecitabine, Bevacizumab CI brief — competitive landscape report
- Docetaxel, Cisplatin, Capecitabine, Bevacizumab updates RSS · CI watch RSS
- Rabin Medical Center portfolio CI
Frequently asked questions about Docetaxel, Cisplatin, Capecitabine, Bevacizumab
What is Docetaxel, Cisplatin, Capecitabine, Bevacizumab?
Docetaxel, Cisplatin, Capecitabine, Bevacizumab is a Small molecule drug developed by Rabin Medical Center.
Who makes Docetaxel, Cisplatin, Capecitabine, Bevacizumab?
Docetaxel, Cisplatin, Capecitabine, Bevacizumab is developed by Rabin Medical Center (see full Rabin Medical Center pipeline at /company/rabin-medical-center).
Is Docetaxel, Cisplatin, Capecitabine, Bevacizumab also known as anything else?
Docetaxel, Cisplatin, Capecitabine, Bevacizumab is also known as Taxotere (Docetaxel), Cisplatin, Xeloda (Capecitabine), Avastin (Bevacizumab.
What development phase is Docetaxel, Cisplatin, Capecitabine, Bevacizumab in?
Docetaxel, Cisplatin, Capecitabine, Bevacizumab is in Phase 1.
Related
- Manufacturer: Rabin Medical Center — full pipeline
- Also known as: Taxotere (Docetaxel), Cisplatin, Xeloda (Capecitabine), Avastin (Bevacizumab